Clinical Study of Autologous T Cells Modified With ILT3 Chimeric Antigen Receptor for Relapsed/Refractory Acute Myeloid Leukemia (M4/M5)
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Anti ILT3 CAR T cell therapy-Carbiogene Therapeutics (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Carbiogene Therapeutics
Most Recent Events
- 24 Mar 2021 New trial record